Kamada Ltd., a global biopharmaceutical company, expects to achieve substantial financial growth in 2026, projecting revenue between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million. At the midpoint, these figures represent year-over-year gains of 13% and 23%, respectively. This growth is entirely organic, stemming from the company's proprietary specialty plasma therapies business and its distribution segment, which handles commercialization of in-licensed third-party biopharmaceutical products.
The company anticipates ending 2025 with approximately $75 million in cash and meeting full-year 2025 revenue of $178-$182 million and adjusted EBITDA of $40-$44 million. Kamada plans to publish its 2025 financial results during the first half of March. Amir London, Kamada's Chief Executive Officer, stated that the company enters 2026 from a position of significant commercial and financial strength, emphasizing progress made over the past year and the ability to consistently convert adjusted EBITDA into operational cash.
Growth in 2026 will be driven primarily by Kamada's specialty plasma-derived therapeutics business, including increased sales in the U.S. market and expanded sales of products such as KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG® in markets outside the U.S. The company's Distribution segment is also expected to contribute significantly, particularly through the launch of additional biosimilar products in the Israeli market and expansion into the Middle East and North Africa region. For more information on Kamada's strategic initiatives, visit https://www.sec.gov.
Additionally, Kamada's plasma collection operations in Texas will support sales growth. The company operates three plasma collection centers in Texas, with the Houston and San Antonio sites each having an annual collection capacity of approximately 50,000 liters of plasma. At full capacity, each site is estimated to contribute $8 million to $10 million in annual revenue. Kamada plans to increase plasma collection at all three centers, reducing dependency on third-party suppliers and positioning itself as a supplier for industry peers. The Kamada Plasma unit is noted as one of a limited number of specialty plasma collection firms in the U.S.
This projected growth is considered achievable despite reduced GLASSIA royalty payments from Takeda Pharmaceutical Co. Ltd., with 2026 marking the first full year under a lower rate. London highlighted this as a testament to the company's resilience and strategic diversification. Beyond organic growth, Kamada is focused on new business development deals and acquisitions, which are expected to enrich its current portfolio of marketed products and generate synergies with existing commercial operations.
The company's forward-looking statements are based on current knowledge and expectations but are subject to risks and uncertainties, including geopolitical conflicts in the Middle East, potential tariffs, regulatory delays, and other factors detailed in filings with the U.S. Securities and Exchange Commission. These statements speak only as of the announcement date, and Kamada undertakes no obligation to update them except as required by law. The original release can be viewed at https://www.newmediawire.com.
